• WP1066: A Precision JAK2/STAT3 Inhibitor for Cancer and Bone

  2026-07-10

  Explore the unique advantages of WP1066, a potent JAK2/STAT3 inhibitor, in dissecting cancer and bone regeneration pathways. This article delivers advanced, application-focused insights and protocol guidance distinct from prior reviews.

• MK 0893: Glucagon Receptor Antagonist for Diabetes Research

  2026-07-09

  MK 0893 stands out as a selective, nanomolar-potency glucagon receptor antagonist, enabling robust investigation of GCGR signaling in type 2 diabetes models. Its unique allosteric inhibition, high oral bioavailability, and proven translational relevance make it a premier tool for both in vitro and in vivo metabolic research.

• SGC-CBP30: Advancing CREBBP/EP300 Inhibition in Lung Cancer

  2026-07-09

  This thought-leadership article explores how SGC-CBP30, a potent and selective CREBBP/EP300 bromodomain inhibitor from APExBIO, empowers translational researchers to interrogate super-enhancer hijacking and transcriptional coactivator function in early-stage lung adenocarcinoma. Integrating mechanistic insights from recent landmark studies and practical guidance, it positions SGC-CBP30 as a transformative tool in epigenetics and cancer biology research.

• A20 Modulates NLRP3 Inflammasome in AKI via Oxidized Self-DN

  2026-07-08

  This study reveals that the ubiquitin-editing enzyme A20 attenuates acute kidney injury (AKI) by suppressing inflammation driven by oxidized self-DNA. By inhibiting both the cGAS-STING pathway and NLRP3 inflammasome, A20 mitigates pyroptosis and tissue damage, highlighting new therapeutic strategies for AKI and related inflammation-driven conditions.

• Harpagoside and PTX Overcome EGFR-Mutant NSCLC Resistance vi

  2026-07-08

  This study demonstrates that combining harpagoside, a natural compound from Xuandanqingjin decoction, with paclitaxel (PTX) overcomes acquired resistance in EGFR-mutant non-small-cell lung cancer (NSCLC). The research highlights the synergistic induction of apoptosis and ferroptosis through Nrf2 pathway suppression, providing a mechanistic basis for new strategies against resistant lung adenocarcinoma.

• DiscoveryProbe Metabolism-related Compound Library: Applied

  2026-07-07

  The DiscoveryProbe™ Metabolism-related Compound Library uniquely empowers metabolic and antiviral research by offering 493 well-characterized, cell-permeable small molecules. Its ready-to-use format streamlines high-throughput metabolic enzyme screening and pathway elucidation in both classic and cutting-edge experimental models.

• Polygodial as a TRPA1 Channel Activator: Workflow & Insights

  2026-07-07

  Polygodial delivers targeted, reproducible activation of TRPA1 channels, streamlining experimental workflows in sensory neuron and epithelial signaling research. Its rapid solubility and reliable performance make it a top choice for dissecting membrane transporter pathways and neurophysiological mechanisms.

• AT13387 in Cancer Biology: Unraveling Hsp90 Inhibition and R

  2026-07-06

  Explore the advanced mechanisms of the Hsp90 inhibitor AT13387 in cancer biology research. This article uniquely bridges high-affinity Hsp90 inhibition with emerging insights into regulated cell death, providing novel assay perspectives for apoptosis and cell cycle arrest studies.

• 11β-HSD1 Inhibition Reduces Liver Fibrosis via Notch Suppres

  2026-07-06

  This study demonstrates that a novel 11β-HSD1 inhibitor significantly attenuates liver fibrosis in a thioacetamide-induced mouse model by suppressing the Notch signaling pathway and enhancing NK cell-mediated immune responses. These mechanistic insights highlight new therapeutic avenues for metabolic dysfunction-associated steatotic liver disease (MASLD) and inform the design of next-generation liver fibrosis models.

• Optimizing Storage for LNP-Formulated Self-Replicating RNA V

  2026-07-05

  This study systematically evaluates how storage conditions impact the stability and in vivo potency of lipid nanoparticle (LNP)-formulated self-replicating RNA vaccines. The findings provide evidence-based protocols for maintaining vaccine efficacy, offering important guidance for both vaccine development and preclinical research workflows.

• Magneto-Piezoelectric Scaffolds Activate JAK2-STAT3 in Bone

  2026-07-04

  The referenced ACS Nano study introduces a multifunctional scaffold integrating magneto-piezoelectric nanoparticles to both disrupt biofilms and activate oxidative phosphorylation in Icam1+ macrophages. This dual-action platform leverages JAK2-STAT3 signaling to enhance bone regeneration in infectious defect models, demonstrating a significant advance for orthopedic tissue engineering.

• CDK4/6 and BET Inhibition Synergizes to Reverse EMT in PDAC

  2026-07-03

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition in pancreatic ductal adenocarcinoma synergistically suppresses tumor growth and reverses epithelial-to-mesenchymal transition (EMT) by modulating GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling. This mechanistic insight addresses a critical paradox in single-agent therapies and informs the refinement of targeted preclinical combination strategies.

• Prevotella copri Drives Breast Cancer via IPyA Depletion and

  2026-07-03

  This study reveals that enrichment of Prevotella copri in the gut microbiota of breast cancer patients accelerates tumor progression by depleting host indole-3-pyruvic acid (IPyA), a physiologic anti-cancer metabolite. Mechanistic experiments show this depletion promotes UHRF1-mediated inactivation of the AMPK pathway, highlighting a novel microbiome-metabolite axis in breast cancer biology.

• Acetylcholine Chloride: Enabling Translational Breakthroughs

  2026-07-02

  Discover how Acetylcholine Chloride advances gut-brain cholinergic signaling research and translational neuroscience. This article explores innovative assay strategies, mechanistic insights, and future directions, offering a deeper perspective on the acetylcholine neurotransmitter's pivotal role.

• Resazurin Sodium Salt: Fluorogenic Indicator for Cell Viabil

  2026-07-02

  Resazurin sodium salt is a highly sensitive fluorogenic oxidation-reduction indicator used to quantify cell viability and cytotoxicity in biological assays. It enables rapid, reproducible assessment of cell proliferation, particularly in high-throughput screening and cancer research. Proper optimization of concentration and incubation parameters is critical to avoid assay artifacts and ensure accurate results.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page